Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Woman Of The Year: Merck's Julie Gerberding On 'Three Vs' For Success

Executive Summary

Accepting Healthcare Businesswomen's Association's 2018 Woman of the Year award, Gerberding shares the principles that have guided her career.

You may also be interested in...



MedImmune's Bahija Jallal On Changing The Diversity Narrative

Bahija Jallal, vice president of AstraZeneca and head of MedImmune, told a packed room of mostly female health care employees that in her career she has "followed her heart and the science" to reach goals she had not imagined possible, as she accepted the Healthcare Businesswomen's Association's 2017 Woman of the Year award.

Evolution of Rx Drug Promotion: Researchers Eye Data Brokers, Digital Tools, Global Influencers

US FDA staff acknowledge the challenge of assessing promotions on the internet as experts note trends and topics for future research, including the use of metadata and embedded advertisements, TikTok promotions, and DTC ads extending into countries that prohibit them.

Divided US FDA AdComm Backs Molnupiravir Authorization But Wants More Studies

In 13-10 vote, panel finds reduction in COVID-19 hospitalizations and deaths outweighs risks. Four members say FDA should reconsider authorization if a more effective and safer therapy comes along. They concur molnupiravir should not be recommended for use in pregnancy but available to those who want it.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel